The Big Question: Can France Catch Up in the Covid Vaccine Race?
Feb 15 2021, 6:14 PM
February 14 2021, 1:30 PM
February 15 2021, 6:14 PM
(Bloomberg Opinion) This is one of a series of interviews by Bloomberg Opinion columnists on how to solve todayâs most pressing policy challenges. It has been condensed and edited.
(Bloomberg Opinion)
This is one of a series of interviews by Bloomberg Opinion columnists on how to solve todayâs most pressing policy challenges. It has been condensed and edited.
Lionel Laurent: Despite a rich history of scientific breakthroughs, from Louis Pasteurâs rabies vaccine to the discovery of HIV in the 1980s, France is the only permanent member of the UN Security Council not to have its own Covid-19 vaccine. Doses have been administered to just over 3% of the French population, below the European Union average and well behind the U.K. and U.S. Youâre a French-American professor of economics in Paris and co-author of a Ja
A This is one of a series of interviews by Bloomberg Opinion columnists on how to solve today’s most pressing policy challenges. It has been condensed and edited.
Lionel Laurent: Despite a rich history of scientific breakthroughs, from Louis Pasteur’s rabies vaccine to the discovery of HIV in the 1980s, France is the only permanent member of the UN Security Council not to have its own Covid-19 vaccine.
Doses have been administered to just over 3% of the French population, below the European Union average and well behind the UK and US. You’re a French-American professor of economics in Paris and co-author of a Jan. 2021 report on the French pharmaceutical industry’s struggle to innovate. Is France’s lagging performance in the Covid vaccine race a case of bad luck, or something deeper?
| UPDATED: 12:38, Wed, Feb 3, 2021
Link copied Sign up for our columnists plus the most commented stories driving conversation
SUBSCRIBE Invalid email
When you subscribe we will use the information you provide to send you these newsletters.
Sometimes they ll include recommendations for other related newsletters or services we offer.
Our Privacy Notice explains more about how we use your data, and your rights.
You can unsubscribe at any time.
France’s slow vaccine roll-out has been the subject of anguished debate since early January, when it became clear that the country’s cautious approach was leaving it behind its neighbours – the UK in particular. According to Our World in Data, the UK has vaccinated almost 11 million people, whereas France has only vaccinated 1.6 million against coronavirus. Against this background, the news Institut Pasteur had abandoned its plan to develop a COVID-19 vaccine with the US pharma giant Merck has set off intense recriminations over
You can now study a Master’s in Climate Change & Sustainable Finance at EDHEC Business School. We look at what makes the course unique, who it is for, and how to apply
Share:
MIROVA, an affiliate of Natixis Investment Managers specialising in sustainable finance, announces it has signed up to become a ‘Mission-led Company
1 , a French accreditation whereby signatories must define their raison d être and one or more social, societal or environmental objectives beyond profit.
The B Corp
Receiving the B Corp
TM 2 certification, after an evaluation process which awarded Mirova an excellent score, is an assurance of the credibility of the company s entire corporate responsibility approach. The label is recognised internationally, and is testament to Mirova s environmental and social commitment.
Mission statement
By setting out its raison d être and social and environmental objectives in its articles of association today, Mirova is formalising its mission to increase its positive impact on both environmental issues and inequality: